Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aurinia Pharmaceuticals ( (AUPH) ) just unveiled an announcement.
Aurinia Pharmaceuticals announced it will release its second quarter 2025 financial and operational results on July 31, 2025, before market opening. The company will host a conference call and webcast to discuss the results, reflecting its ongoing commitment to transparency and engagement with stakeholders.
The most recent analyst rating on (AUPH) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.
Spark’s Take on AUPH Stock
According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.
Aurinia Pharmaceuticals has a solid overall stock score, driven by strong financial performance and positive earnings call highlights. However, the high valuation and mixed technical signals, along with potential risks from patent litigation and market competition, moderate the score.
To see Spark’s full report on AUPH stock, click here.
More about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company specializing in therapies for autoimmune diseases with significant unmet medical needs. The company is known for LUPKYNIS, the first FDA-approved oral therapy for adult patients with active lupus nephritis, and is developing aritinercept for potential autoimmune disease treatments.
Average Trading Volume: 1,502,433
Technical Sentiment Signal: Buy
Current Market Cap: $1.17B
For detailed information about AUPH stock, go to TipRanks’ Stock Analysis page.